Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine

Endocrine Practice

Volumn 18, Issue 4, 2012, Pages 558-562

  King, Allen B ^a   Clark, Dawn ^a   Wolfe, Gary S ^a  

^a Diabetes Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; INSULIN LISPRO;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DIET RESTRICTION; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; POSTPRANDIAL STATE; SELF MONITORING;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BREAKFAST; CALIFORNIA; DIABETES MELLITUS, TYPE 1; DIABETIC DIET; DRUG CHRONOTHERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84864668198     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12042.OR     Document Type: Article

References (19)

1. King AB, Clark D, Wolfe GS. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus. Endocr Pract. 2012;18:382-386.
2. King AB. How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose mon-itoring. Endocr Pract. 2010;16:428-432.
3. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabe-tes mellitus given meal-time lispro insulin. Diabet Med. 2004;21:1213-1220.
4. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutane-ous insulin infusion (lispro) in type 1 diabetes: a random-ized open parallel multicenter study published correction appears in Diabetes Care. 2009;32:1944. Diabetes Care. 2009;32:1170-1176.
5. Hamann A, Matthaei S, Rosak C, Silvestre L (HOE901/4007 Study Group). A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-1744
6. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insu-lin: effcacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes\the glargine and aspart study (GLASS); a randomised cross-over study. Diabetes Res Clin Pract. 2007;77:215-222.
7. Bolli GB, Songini M, Trovati M, et al. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with type 1 diabetes. Nutr Metab Cardiovasc Dis. 2009;19:571-579.
8. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circa-dian rhythmicity and sleep in human glucose regulation. Endocr Rev. 1997;18:716-738.
9. Jones SM, Quarry JL, Caldwell-McMillian M, Mauger DT, Gabbay RA. Optimal insulin pump dosing and post-prandial glycemia following a pizza meal using the con-tinuous glucose monitoring system. Diabetes Technol Ther. 2005;7:233-240.
10. Bernstein G. The diabetic stomach: management strat-egies for clinicians and patients. Diabetes Spectrum. 2000;13:11-21.
11. Berndt-Zipfel C, Köthe L, Nawrodt B, Mraz B, Patzelt-Bath A, Nauck MA. Glycaemic rises after waking up in response to an alarm clock in type 1-diabetic patients ana-lysed with continuous glucose monitoring (GlucoDay® S). Exp Clin Endocrinol Diabetes. 2011;119:56-58.
12. Lepore M, Pampanelli S, Fanelli C. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
13. Hatlehol R. The infuence of fasting on the blood sugar in diabetes. Acta Med Scand. 1924;60(suppl 8):176-180.
14. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to noc-turnal surges in growth hormone secretion. N Engl J Med. 1985;312:1473-1479.
15. Carroll MF, Schade DS. The dawn phenomenon revis-ited: implications for diabetes therapy Endocr Pract. 2005; 11:55-64.
16. Perriello G, De Feo P, Torlone E, et al. The dawn phenom-enon in type 1 (insulin-dependent) diabetes mellitus: mag-nitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity Diabetologia. 1991;34:21-28.
17. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharma-cokinetic and metabolic effects. Diabetes Care. 2003;26: 2027-2031.
18. King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007;1:42-46.
19. Alemzadeh R, Hoffmann RG, Dasgupta M, Parton E. Development of optimal kids insulin dosing system formu-las for young children with type 1 diabetes mellitus pub-lished online ahead of print January 12, 2012. Diabetes Technol Ther. PMID: 22239470.